In Segment C, participants will receive ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Contributors will acquire treatment until finally condition progression or even the individuals are not able to tolerate the study drugs. Ubiquitin-relevant proteins that regulate the stability of key Tremendous enhancer-mediated proteins https://benitol665xis8.wikiinside.com/user